Molecular Designs Secures First FDA Clearance for Respiratory Test
Molecular Designs announced on November 13, 2026 that the US Food and Drug Administration (FDA) had granted 510(k) clearance K262789 for its SimplicityDx Panel FluA/FluB/RSV, the company’s first FDA-cleared assay. The multiplex real-time RT-PCR test qualitatively detects and differentiates influenza A, influenza B and respiratory syncytial virus (RSV) RNA in anterior nasal swab specimens from individuals with signs and symptoms of respiratory tract infection. The panel is for prescription use…